Introduction
============

Atrial fibrillation (AF) is a cardiac arrhythmia seen frequently in clinical practice and increases in prevalence with advancing age.[@b1-cia-9-301]--[@b5-cia-9-301] AF is also the most common rhythm abnormality in patients with chronic kidney disease (CKD).[@b6-cia-9-301] An estimated 19%--24% of patients with CKD are diagnosed with AF, and the combined prevalence of these conditions increases as the population ages. AF and CKD share a number of risk factors, including increasing age and pre-existing cardiovascular disease, including hypertension, diabetes mellitus, coronary artery disease (CAD), and chronic heart failure, and the close relationship between AF and CKD has attracted attention.[@b7-cia-9-301]--[@b9-cia-9-301] Both AF and CKD confer a significant morbidity burden and are associated with a worse outcome.[@b10-cia-9-301]--[@b12-cia-9-301] With increasing life expectancy, the elderly are the most rapidly expanding portion of the world population, making the association between AF, CKD, and mortality an even more significant public health concern.

The close link between AF and renal function has been shown in previous studies involving patients with end-stage renal disease (ESRD).[@b13-cia-9-301]--[@b16-cia-9-301] However, patients with ESRD represent a small proportion of individuals with decreased renal function, and much less is clear about the correlation between AF and less severe decline in renal function.[@b17-cia-9-301]--[@b21-cia-9-301] Whether different types of AF have different associations with renal function also remains unclear, and may have potential clinical implications for the management of high-risk patients. Meanwhile, age, race, and comorbidity have an unavoidable effect on the bidirectional relationship between AF and renal function, and taking these factors into consideration is necessary for an indepth analysis of this relationship. However, few studies have addressed this association in elderly Chinese patients with CAD.

A close relationship has been demonstrated between AF and poor clinical outcome in patients with ESRD.[@b2-cia-9-301],[@b22-cia-9-301] However, whether the relationship is similarly present in patients with less severe decline of renal function has not been extensively studied.[@b23-cia-9-301] Different types of AF may have different prognostic significance, and further studies are needed to elucidate this possibility. Given the contribution of age, race, and comorbidity to the complexity of the problem, we felt a study was necessary to evaluate the impact of different types of AF on mortality in elderly Chinese CAD patients with and without CKD. To address the knowledge gap, the current study investigated the prevalence of different types of AF in elderly Chinese patients with CAD, assessed the burden of decreased renal function on development of different types of AF, and evaluated the influence of different types of AF on survival in patients stratified according to the presence of CKD.

Methods
=======

Study population
----------------

The study cohort comprised 1,050 Chinese patients aged ≥60 years with CAD who were enrolled consecutively at the Department of Geriatric Cardiology, Chinese People's Liberation Army General Hospital. Their median age was 86 (range 60--104) years. The Chinese People's Liberation Army General Hospital was their designated hospital and held their integrated long-term medical and final death records, which made it easier for us to follow them up effectively and judge endpoints accurately. Using the American College of Cardiology (ACC)/American Heart Association (AHA) or European Society of Cardiology (ESC) guidelines, the lead physicians identified patients with CAD on the basis of history, symptoms of typical angina, cardiac markers, and specific cardiac examinations, including electrocardiogram (resting and exercise), echocardiography, radionuclide imaging, computed tomography, and coronary angiography.[@b24-cia-9-301]--[@b26-cia-9-301]

Definition of study variables
-----------------------------

Body mass index was calculated as weight in kilograms divided by the square of height in meters. Mean systolic and diastolic blood pressure (BP) was systematically determined from five measurements. A standard 12-lead electrocardiogram was recorded in all participants using strictly standardized procedures with identical electrocardiographic equipment. Several structural parameters were derived from the echocardiographic data. Left ventricular ejection fraction was measured by Simpson's method.[@b27-cia-9-301] Left ventricular mass was calculated according to the formula described by Devereux et al,[@b28-cia-9-301] and left ventricular mass index was obtained by dividing the left ventricular mass by body surface area. In light of the ACC/AHA/ESC guidelines, patients with AF were detected by the lead physicians on the basis of medical record documentation and electrocardiographic evidence, and classified as paroxysmal, persistent, or permanent.[@b29-cia-9-301] Chronic heart failure was diagnosed by the lead physicians according to the ESC guidelines.[@b30-cia-9-301] Hypertension was defined as either mean systolic BP ≥140 mmHg, mean diastolic BP ≥90 mmHg, or use of antihypertensive medication. Diabetes mellitus was defined as being present if participants had a fasting serum glucose ≥7 mmol/L or used insulin or oral hypoglycemic medications. History of smoking was defined as a history of cigarette use on a regular basis (more than one cigarette per day). Estimated glomerular filtration rate (eGFR) was calculated using the modified Modification of Diet in Renal Disease equation based on data for the Chinese population: $$175 \times \text{serum\ creatinine\ (mg/dL)}^{- 1.234} \times \text{age\ (years)}^{- 0.179}( \times 0.79\text{if\ female}).$$[@b31-cia-9-301]CKD was defined as eGFR \<60 mL/minute/1.73 m^2^ according to the recommendations of the National Kidney Foundation.[@b32-cia-9-301] Other blood assays, including hemoglobin, serum albumin, glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum sodium, potassium, calcium and phosphorus were carried out at the central laboratory in the Department of Biochemistry, Chinese People's Liberation Army General Hospital.

Follow-up and outcome
---------------------

Given the high incidence of multiple organ failure in the elderly as well as the priority of all-cause mortality in outcome studies, the primary end point assessed in the current study was all-cause death. The mean follow-up period consisted of 417 days (median 317 days, interquartile range 185--557 days). No patient dropped out during the study period. Follow-up data were tracked directly from medical records and telephone interviews. Death was ascertained from the death record, ie, a legal document including time, site, and other information.

Statistical analysis
--------------------

Patient data were described by the mean and standard deviation for continuous variables with a normal distribution, median and interquartile range for non-normally distributed continuous variables, and number and percentage of the total for categorical variables. Characteristics between patients with different types of AF and those without AF were matched using the Student's *t*-test for continuous variables (normal distribution), the Mann-- Whitney *U* test for continuous variables (abnormal distribution), and the chi-squared test for categorical variables. Multinomial logistic regression analysis was used to observe the relationship between eGFR and CKD with different types of AF after adjusting for age, sex, history of smoking, body mass index, chronic heart failure, hypertension, diabetes mellitus, mean systolic and diastolic BP, heart rate, left ventricular ejection fraction, interventricular septum, left ventricular posterior wall, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, left ventricular mass index, hemoglobin, serum albumin, glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and serum sodium, potassium, calcium, and phosphorus. Cox regression models including adjustment for the same confounders as described above were used to examine the adjusted effect of different types of AF on mortality for the patients grouped by presence of CKD. A two-tailed *P*\<0.05 was considered to be statistically significant. All analyses were done using Statistical Package for the Social Sciences version 17 software (SPSS Inc, Chicago, IL, USA).

Results
=======

The study cohort comprised 1,050 patients, of whom 219 (20.9%) had a diagnosis of AF. Among the patients with AF, 128 (12.2%) had paroxysmal AF, 44 (4.2%) had persistent AF, and 47 (4.5%) had permanent AF. Demographic and clinical characteristics according to presence and types of AF are summarized in [Table 1](#t1-cia-9-301){ref-type="table"}. Compared with non-AF patient group, the group of patients with permanent AF (*P*\<0.05), but not those with paroxysmal AF (*P*\>0.05) or persistent AF (*P*\>0.05), contained a significantly higher proportion of patients with CKD. Compared with non-AF patients, eGFR was lower in patients with permanent AF (*P*\<0.05) but not in those with paroxysmal AF (*P*\>0.05) or persistent AF (*P*\>0.05). Meanwhile, chronic heart failure was significantly more common in patients with any type of AF than in non-AF patients (all *P*\<0.05). In addition, there were several differences in echocardiographic, blood pressure, and electrolyte parameters between non-AF patients and those with any type of AF (all *P*≤0.05).

[Table 2](#t2-cia-9-301){ref-type="table"} shows the factors associated with the different types of AF after adjusting for age, sex, history of smoking, body mass index, chronic heart failure, hypertension, diabetes mellitus, mean systolic and diastolic BP, heart rate, left ventricular ejection fraction, interventricular septum, left ventricular posterior wall, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, left ventricular mass index, hemoglobin, serum albumin, glucose, triglycerides, high-density and low-density lipoprotein cholesterol, and serum sodium, potassium, calcium, and phosphorus. eGFR was independently lower and the prevalence of CKD was independently higher in patients with permanent AF (all *P*≤0.05) but not in those with paroxysmal AF (all *P*\>0.05) or persistent AF (all *P*\>0.05).

During follow-up, 106 (15.6%) non-CKD patients and 112 (30.1%) CKD patients died; mortality was significantly higher in AF patients with CKD than in non-AF patients with CKD (36 \[40.9%\] versus 76 \[26.8%\], respectively, *P*\<0.05) but not in those without CKD (17 \[13.0%\] versus 89 \[16.3%\], respectively, *P*\>0.05). [Table 3](#t3-cia-9-301){ref-type="table"} shows the factors correlated with the increased risk of mortality in CKD patients in comparison with non-CKD patients after adjustment for the same confounders as described above. In patients with CKD, paroxysmal AF was strongly associated with a higher independent risk of death (*P*\<0.05), while persistent AF and permanent AF were not associated with a higher independent risk of death (all *P*\>0.05). In contrast, any type of AF had no independent association with mortality (all *P*\>0.05) in patients without CKD. Further, regardless of whether or not patients had CKD, serum levels of hemoglobin, albumin, triglycerides, and phosphorus, as well as heart rate, consistently showed an independent effect with regard to survival.

Discussion
==========

The current study shows that regardless of type, there is a high prevalence of AF in elderly Chinese patients with CAD. Moreover, the study confirms that patients with permanent AF have a lower eGFR and a higher prevalence of CKD, even after adjusting for a broad set of potential confounders. Further, it is demonstrated that, after full adjustment, paroxysmal AF is a strong predictor of an independently increased mortality rate in patients with CKD relative to those without CKD. These observations are extremely relevant to the care of this elderly population and deserve close attention.

In previous studies of patients with ESRD, the prevalence of AF ranged from 3.5% to 27%, depending on the patterns of AF (paroxysmal, persistent, permanent) and associated risk factors.[@b16-cia-9-301] In the general hemodialysis population, the prevalence of AF was 27.0%, however when patients with paroxysmal AF were excluded, the prevalence was 23.5%, and when only those with permanent AF were included, the prevalence was 13.9%.[@b16-cia-9-301] Patients with ESRD, however, represent a small proportion of individuals with a decreased renal function, and the correlation of AF with less severe decline of renal function has not been well evaluated.[@b17-cia-9-301]--[@b21-cia-9-301] In the Atherosclerosis Risk in Community study, Alonso et al proposed a progressively higher risk of AF with CKD.[@b17-cia-9-301] Horio et al conducted a study in 1,118 hypertensive patients and revealed an increased risk of AF in those with CKD.[@b21-cia-9-301] In contrast, a study of patients with CKD found that the association between eGFR level and AF prevalence was no longer significant after adjustment.[@b20-cia-9-301] Moreover, the association between different types of AF and renal function may have implications for the clinical management of high-risk patients. Meanwhile, age, race, and comorbidity had an unavoidable effect on the relationship between AF and renal function, and taking these factors into consideration is important for indepth analysis of this relationship. However, data on the association between different types of AF and renal function is extremely limited in elderly Chinese patients with CAD. The observations from our study further confirm that the relationship between renal function and permanent AF is independently significant, which is an important supplement to previous reports[@b17-cia-9-301]--[@b21-cia-9-301] and subdivides this association in elderly Chinese patients with CAD.

Multiple pathophysiological mechanisms could underlie the relationship between AF and renal function. Neurohormonal activation has been implicated in the progression of renal damage and development of cardiovascular disease. Activation of the renin--angiotensin--aldosterone system has been documented in patients with CKD, and there is evidence suggesting that angiotensin also induces cardiac fibroblast proliferation and cardiac hypertrophy.[@b33-cia-9-301],[@b34-cia-9-301] Meanwhile, increased sympathetic activity has been proposed to promote arrhythmogenesis in patients with CKD.[@b33-cia-9-301] In addition to neurohormonal activation, inflammation has been considered as a contributor to the increased risk of AF in patients with CKD. Inflammatory markers are elevated in patients with CKD, and inflammation plays a significant role in the pathogenesis of AF.[@b19-cia-9-301] Further, structural and electrical atrial remodeling has shed light on the epidemiology of AF in patients with CKD. Prior studies have noted that increasing left atrial diameter and left ventricular hypertrophy related to CKD contributes to an increased risk of AF.[@b19-cia-9-301]

A strong association between AF and mortality has been found in patients with ESRD.[@b2-cia-9-301],[@b22-cia-9-301] For example, a study by Genovesi et al in 476 patients from five dialysis centers in one region of Italy reported that patients with AF had a 65% higher relative risk of death than those without AF.[@b22-cia-9-301] Beyond that, in the Framingham study, Kannel et al found that AF was associated with a 2--3-fold increased risk of mortality in patients with ESRD.[@b2-cia-9-301] However, few studies have analyzed the association between AF and mortality in patients with a less severe decline in renal function.[@b23-cia-9-301] Nakagawa et al published data on 387 Japanese patients, reporting increased mortality rates in patients with AF and decreased eGFR.[@b23-cia-9-301] Considering that age, race, and comorbidity complicate matters further and that different types of AF may have diverse prognostic significance, the present study provides compelling data indicating that elderly Chinese AF patients with CKD, but not those without CKD, have an independently increased risk of mortality. Moreover, the present study findings confirm that the combination of CKD and paroxysmal AF has an independent effect on mortality rate, extending the results of previous studies and detailing the relationship between AF, CKD and mortality in elderly Chinese patients with CAD in more depth.

Several hypotheses have been offered to explain these findings. One possible explanation for the higher mortality rate is a higher incidence of stroke in patients with CKD and AF. It is well established that AF is one of the strongest predictors of ischemic stroke.[@b35-cia-9-301] A paper reported by Hart et al supports a higher rate of ischemic stroke in patients with CKD and AF in the Stroke Prevention in Atrial Fibrillation trials.[@b36-cia-9-301] A more plausible explanation linking the increased mortality rate with CKD and AF is that the presence of AF reflects the composite effect of a spectrum of cardiovascular disease mechanisms leading to left atrial enlargement, including vascular stiffness/noncompliance (due to classic atherosclerosis and nonclassic risk factors) present in the metabolic milieu of CKD (ie, abnormal calcium and phosphate metabolism, left ventricular hypertrophy, and sympathetic overactivity).[@b37-cia-9-301] The genesis of AF in patients with CKD is intimately linked with the same mechanisms that predispose these patients to increased risk of cardiovascular death.[@b37-cia-9-301]

In conclusion, the present study finds that all types of AF have a high prevalence in elderly Chinese patients with CAD. Moreover, it underscores that patients with permanent AF are at extremely high risk of increased CKD and decreased eGFR independent of a broad set of potential confounders. Further, after adjustment for these potential confounders, the importance of paroxysmal AF as a strong risk factor for mortality in patients with CKD, but not in those without CKD, is emphasized. It is generally accepted that both CKD and AF are prevalent in the elderly, and thus our findings may have significant public health and clinical implications. Future studies should further delineate the potentially modifiable pathways responsible for this association.
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###### 

Baseline patient characteristics by presence and type of AF

  Characteristics                                                        Non-AF                 Paroxysmal AF          *P*-value[a](#tfn1-cia-9-301){ref-type="table-fn"}   Persistent AF          *P*-value[b](#tfn2-cia-9-301){ref-type="table-fn"}   Permanent AF           *P*-value[c](#tfn3-cia-9-301){ref-type="table-fn"}
  ---------------------------------------------------------------------- ---------------------- ---------------------- ---------------------------------------------------- ---------------------- ---------------------------------------------------- ---------------------- ----------------------------------------------------
  Sample size (%)                                                        831 (79.1)             128 (12.2)                                                                  44 (4.2)                                                                    47 (4.5)               
  Demographics                                                                                                                                                                                                                                                                 
   Age (years)[d](#tfn4-cia-9-301){ref-type="table-fn"}                  86 (81--89)            87 (82--90)            0.116                                                85 (83--91)            0.734                                                85 (81--89)            0.696
   Males (%)                                                             750 (90.3)             110 (85.9)             0.135                                                38 (86.4)              0.561                                                39 (83.0)              0.174
   History of smoking (%)                                                324 (39.0)             39 (30.5)              0.064                                                15 (34.1)              0.516                                                20 (42.6)              0.626
   BMI (kg/m^2^)[e](#tfn5-cia-9-301){ref-type="table-fn"}                23.87 (3.39)           24.19 (3.75)           0.547                                                24.33 (3.69)           0.262                                                23.76 (3.78)           0.835
  Comorbidity                                                                                                                                                                                                                                                                  
   CKD (%)                                                               284 (34.2)             46 (35.9)              0.696                                                18 (40.9)              0.360                                                24 (51.1)              0.018
   Chronic heart failure (%)                                             226 (27.2)             46 (35.9)              0.041                                                26 (59.1)              ,0.001                                               29 (61.7)              ,0.001
   Hypertension (%)                                                      669 (80.5)             101 (78.9)             0.672                                                35 (79.5)              0.876                                                34 (72.3)              0.173
   Diabetes mellitus (%)                                                 339 (40.8)             45 (35.2)              0.226                                                17 (38.6)              0.776                                                16 (34.0)              0.359
  Clinical presentation                                                                                                                                                                                                                                                        
   MSBP (mmHg)[d](#tfn4-cia-9-301){ref-type="table-fn"}                  133 (124--142)         132 (124--143)         0.886                                                133 (126--142)         0.783                                                126 (119--136)         0.002
   MDBP (mmHg)[d](#tfn4-cia-9-301){ref-type="table-fn"}                  69 (64--74)            70 (64--74)            0.373                                                70 (65--77)            0.148                                                71 (63--77)            0.219
   Heart rate (bpm)[d](#tfn4-cia-9-301){ref-type="table-fn"}             72 (64--80)            72 (64--85)            0.289                                                75 (61--82)            0.467                                                76 (64--88)            0.113
   LVEF (%)[d](#tfn4-cia-9-301){ref-type="table-fn"}                     60 (55--63)            60 (58--63)            0.052                                                58 (54--62)            0.155                                                58 (51--62)            0.007
   IVS (mm)[d](#tfn4-cia-9-301){ref-type="table-fn"}                     11 (10--11)            10.0 (10--11)          0.453                                                11 (10--12)            0.140                                                11 (10--11)            0.322
   LVPW (mm)[d](#tfn4-cia-9-301){ref-type="table-fn"}                    10 (10--11)            10 (10--11)            0.555                                                10 (10--11)            0.050                                                10 (9--11)             0.025
   LVESD (mm)[d](#tfn4-cia-9-301){ref-type="table-fn"}                   33 (31--35)            33 (31--35)            0.449                                                34 (32--37)            0.017                                                34 (31--36)            0.061
   LVEDD (mm)[d](#tfn4-cia-9-301){ref-type="table-fn"}                   49 (46--51)            48 (46--51)            0.406                                                50 (47--54)            0.047                                                49 (46--52)            0.660
   LVMI (g/m^2^)[d](#tfn4-cia-9-301){ref-type="table-fn"}                32 (29--34)            33 (30--34)            0.026                                                31 (28--33)            0.111                                                30 (26--33)            0.020
  Laboratory results                                                                                                                                                                                                                                                           
   eGFR (mL/minute/1.73 m^2^)[d](#tfn4-cia-9-301){ref-type="table-fn"}   70.64 (53.45--83.69)   67.80 (53.62--80.20)   0.300                                                66.58 (51.96--81.14)   0.390                                                59.88 (52.49--73.79)   0.003
   Hemoglobin (g/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}             124 (109--138)         123 (106--135)         0.114                                                125 (100--138)         0.566                                                125 (110--141)         0.316
   Serum albumin (g/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}          38.4 (35.4--40.8)      38.0 (35.0--40.1)      0.149                                                38.3 (34.6--41.5)      0.932                                                37.8 (35.9--41.5)      0.664
   Glucose (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}             5.3 (4.8--6.1)         5.6 (5.0--6.2)         0.071                                                5.9 (4.8--6.8)         0.145                                                5.3 (4.6--5.9)         0.428
   Triglycerides (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}       1.23 (0.92--1.76)      1.31 (0.92--1.85)      0.476                                                1.24 (0.80--1.75)      0.609                                                1.10 (0.83--1.51)      0.169
   HDL-c (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}               1.05 (0.87--1.29)      1.03 (0.85--1.21)      0.140                                                1.03 (0.82--1.19)      0.409                                                1.02 (0.92--1.35)      0.899
   LDL-c (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}               2.15 (1.72--2.62)      2.14 (1.65--2.63)      0.437                                                1.89 (1.63--2.43)      0.114                                                2.02 (1.52--2.45)      0.114
   Na^+^ (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}               139 (136--142)         139 (136--142)         0.408                                                140 (136--142)         0.702                                                138 (136--141)         0.554
   Ka^+^ (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}               4.0 (3.7--4.2)         3.9 (3.7--4.2)         0.405                                                4.1 (3.9--4.4)         0.042                                                4.0 (3.7--4.3)         0.669
   Ca^2+^ (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}              2.22 (2.12--2.30)      2.21 (2.10--2.30)      0.435                                                2.22 (2.12--2.33)      0.488                                                2.17 (2.11--2.25)      0.068
   P^5+^ (mmol/L)[d](#tfn4-cia-9-301){ref-type="table-fn"}               1.10 (0.95--1.23)      1.08 (0.94--1.23)      0.726                                                1.12 (0.98--1.22)      0.472                                                1.10 (1.00--1.27)      0.698

**Notes:**

Comparison between patients without and with paroxysmal AF;

comparison between patients without and with persistent AF;

comparison between patients without and with permanent AF;

median (interquartile range);

mean (standard deviation).

**Abbreviations:** AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; MSBP, mean systolic blood pressure; MDBP, mean diastolic blood pressure; LVEF, left ventricular ejection fraction; IVS, interventricular septum; LVPW, left ventricular posterior wall; LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter; LVMI, left ventricular mass index; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.

###### 

Multinomial logistic regression model results for different types of AF

  Different models      Model with eGFR as a variable[a](#tfn6-cia-9-301){ref-type="table-fn"}   Model with CKD as a variable[a](#tfn6-cia-9-301){ref-type="table-fn"}                                                                        
  --------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------- --------------------- ----------------------- ---------------------- -------
  Paroxysmal AF         eGFR (mL/minute/1.73 m^2^)                                               0.999 (0.990--1.008)                                                    0.824                 CKD                     0.909 (0.583--1.418)   0.675
  Age (years)           1.032 (0.999--1.066)                                                     0.055                                                                   Age (years)           1.033 (1.000--1.067)    0.049                  
  CHF                   1.926 (1.214--3.053)                                                     0.005                                                                   CHF                   1.956 (1.235--3.099)    0.004                  
  Heart rate (bpm)      1.014 (1.001--1.026)                                                     0.033                                                                   Heart rate (bpm)      1.013 (1.001--1.026)    0.035                  
  HDL-c (mmol/L)        0.454 (0.218--0.945)                                                     0.035                                                                   HDL-c (mmol/L)        0.446 (0.214--0.928)    0.031                  
  Persistent AF         eGFR (mL/minute/1.73 m^2^)                                               1.006 (0.991--1.022)                                                    0.424                 CKD                     0.805 (0.385--1.681)   0.564
  Age (years)           1.053 (0.999--1.111)                                                     0.055                                                                   Age (years)           1.052 (0.998--1.110)    0.058                  
  CHF                   4.577 (2.189--9.567)                                                     \<0.001                                                                 CHF                   4.529 (2.172--9.446)    \<0.001                
  MDBP (mmHg)           1.055 (1.005--1.108)                                                     0.032                                                                   MDBP (mmHg)           1.055 (1.005--1.108)    0.030                  
  Permanent AF          eGFR (mL/minute/1.73 m^2^)                                               0.975 (0.958--0.993)                                                    0.007                 CKD                     2.005 (1.002--4.014)   0.050
  Age (years)           1.069 (1.012--1.129)                                                     0.018                                                                   Age (years)           1.072 (1.015--1.133)    0.012                  
  CHF                   5.082 (2.436--10.605)                                                    \<0.001                                                                 CHF                   5.044 (2.415--10.538)   \<0.001                
  MSBP (mmHg)           0.936 (0.902--0.971)                                                     \<0.001                                                                 MSBP (mmHg)           0.938 (0.904--0.973)    0.001                  
  MDBP (mmHg)           1.110 (1.051--1.172)                                                     \<0.001                                                                 MDBP (mmHg)           1.107 (1.049--1.169)    \<0.001                
  Hemoglobin (g/L)      1.021 (1.001--1.042)                                                     0.041                                                                   Hemoglobin (g/L)      1.019 (0.999--1.040)    0.063                  
  Serum albumin (g/L)   1.101 (0.997--1.216)                                                     0.058                                                                   Serum albumin (g/L)   1.096 (0.992--1.210)    0.071                  

**Notes:**

Adjusted for age, sex, history of smoking, body mass index, chronic heart failure, hypertension, diabetes mellitus, mean systolic blood pressure, mean diastolic blood pressure, heart rate, left ventricular ejection fraction, interventricular septum, left ventricular posterior wall, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, left ventricular mass index, hemoglobin, serum albumin, glucose, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, serum sodium, potassium, calcium and phosphorus.

**Abbreviations:** AF, atrial fibrillation; bpm, beats per minute; HR, hazard ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; CHF, chronic heart failure; HDL-c, high-density lipoprotein cholesterol; MDBP, mean diastolic blood pressure; MSBP, mean systolic blood pressure.

###### 

Cox regression model results for survival of patients with and without CKD

  Population               Independent variables[a](#tfn8-cia-9-301){ref-type="table-fn"}   HR (95% CI)            *P*-value
  ------------------------ ---------------------------------------------------------------- ---------------------- -----------
  Without CKD              Paroxysmal AF                                                    0.726 (0.364--1.449)   0.364
  Persistent AF            0.712 (0.201--2.527)                                             0.600                  
  Permanent AF             0.597 (0.143--2.491)                                             0.479                  
  Heart rate (bpm)         1.017 (1.006--1.029)                                             0.003                  
  Hemoglobin (g/L)         0.975 (0.963--0.987)                                             \<0.001                
  Serum albumin (g/L)      0.936 (0.878--0.997)                                             0.042                  
  Triglycerides (mmol/L)   1.274 (1.028--1.578)                                             0.027                  
  P^5+^ (mmol/L)           2.211 (1.233--3.966)                                             0.008                  
  With CKD                 Paroxysmal AF                                                    1.972 (1.103--3.527)   0.022
  Persistent AF            1.326 (0.571--3.076)                                             0.511                  
  Permanent AF             0.506 (1.180--1.425)                                             0.197                  
  Age (years)              1.051 (1.014--1.089)                                             0.006                  
  Heart rate (bpm)         1.015 (1.001--1.030)                                             0.038                  
  Hemoglobin (g/L)         0.984 (0.973--0.996)                                             0.007                  
  Serum albumin (g/L)      0.889 (0.839--0.942)                                             \<0.001                
  Triglycerides (mmol/L)   0.743 (0.562--0.983)                                             0.038                  
  P^5+^ (mmol/L)           2.302 (1.545--3.429)                                             \<0.001                

**Notes:**

Adjusted for age, sex, history of smoking, body mass index, chronic heart failure, hypertension, diabetes mellitus, mean systolic blood pressure, mean diastolic blood pressure, heart rate, left ventricular ejection fraction, interventricular septum, left ventricular posterior wall, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, left ventricular mass index, hemoglobin, serum albumin, glucose, triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol, serum sodium, potassium, calcium and phosphorus.

**Abbreviations:** CKD, chronic kidney disease; HR, hazard ratio; CI, confidence interval; AF, atrial fibrillation.

[^1]: These authors are joint first authors
